###begin article-title 0
A tamoxifen inducible knock-in allele for investigation of E2A function
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 713 720 713 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a </italic>
###xml 844 847 844 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
E-proteins are transcription factors important for the development of a variety of cell types, including neural, muscle and lymphocytes of the immune system. E2A, the best characterized E-protein family member in mammals, has been shown to have stage specific roles in cell differentiation, lineage commitment, proliferation, and survival. However, due to the complexity of E2A function, it is often difficult to separate these roles using conventional genetic approaches. Here, we have developed a new genetic model for reversible control of E2A protein activity at physiological levels. This system was created by inserting a tamoxifen-responsive region of the estrogen receptor (ER) at the carboxyl end of the tcfe2a gene to generate E2AER fusion proteins. We have characterized and analyzed the efficiency and kinetics of this inducible E2AER system in the context of B cell development.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 110 116 110 116 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 252 261 252 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vitro </italic>
###xml 382 388 382 388 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 514 522 514 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 388 392 <span type="species:ncbi:10090">mice</span>
B cell development has been shown previously to be blocked at an early stage in E2A deficient animals. Our E2AER/ER mice demonstrated this predicted block in B cell development, and E2AER DNA binding activity was not detected in the absence of ligand. In vitro studies verified rapid induction of E2AER DNA binding activity upon tamoxifen treatment. While tamoxifen treatment of E2AER/ER mice showed inefficient rescue of B cell development in live animals, direct exposure of bone marrow cells to tamoxifen in an ex vivo culture was sufficient to rescue and support early B cell development from the pre-proB cell stage.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 270 273 270 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 432 435 432 435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 435 443 435 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
The E2AER system provides inducible and reversible regulation of E2A function at the protein level. Many previous studies have utilized over-expression systems to induce E2A function, which are complicated by the toxicity often resulting from high levels of E2A. The E2AER model instead restores E2A activity at an endogenous level and in addition, allows for tight regulation of the timing of induction. These features make our E2AER ex vivo culture system attractive to study both immediate and gradual downstream E2A-mediated events.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a </italic>
###xml 199 200 199 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 374 375 374 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
E2A, encoded by the tcfe2a gene and a member of the E-protein family, is a basic helix-loop-helix (HLH) transcription factor critical for regulating gene expression in several developmental systems [1]. Originally identified as an immunoglobulin (Ig) enhancer binding factor, E2A has since largely been studied for its roles during the development of B and T lymphocytes [2,3]. E2A participates in various aspects of lymphocyte development including lineage commitment, initiation of lineage specific gene expression, rearrangement of B and T cell receptor genes, and differentiation through multiple developmental stages. In addition to roles in lineage commitment and cell differentiation, E2A has also been shown to regulate cell cycle, proliferation, and survival.
###end p 9
###begin p 10
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 370 371 370 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 633 635 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
E-proteins, including E2A, HEB, and E2-2 in mammals, function as dimers to bind DNA and regulate gene expression. E2A homodimers are the primary E-protein dimers functioning in B cells, whereas E2A-HEB heterodimers are the primary dimers functioning in T cells [4-6]. Recent data suggests that E2-2 homodimers are critical for plasmacytoid dendritic cell development [7,8]. E2A also serves as an important dimerization partner for tissue specific HLH transcription factors outside of the lymphoid system. For example, E2A forms dimers with NeuroD and MyoD, key regulators of neuronal and skeletal muscle development, respectively [9-11]. Since E2A is the common factor for multiple lineage specific HLH transcription factor dimers, novel tools for targeting and manipulating E2A function can benefit a range of developmental biology research areas.
###end p 10
###begin p 11
###xml 235 241 235 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a</italic>
###xml 521 523 521 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 524 526 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 775 784 775 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 815 817 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 876 884 876 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 949 951 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 1070 1073 1070 1073 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 105 110 <span type="species:ncbi:10090">mouse</span>
###xml 350 355 <span type="species:ncbi:10090">mouse</span>
###xml 515 519 <span type="species:ncbi:10090">mice</span>
###xml 743 748 <span type="species:ncbi:10090">mouse</span>
###xml 826 831 <span type="species:ncbi:10090">mouse</span>
###xml 1150 1155 <span type="species:ncbi:10090">mouse</span>
Here we have developed a new genetic model to examine E2A function. We have established an inducible E2A mouse model by inserting a tamoxifen-responsive region of the estrogen receptor (ER) ligand binding domain at the carboxyl end of tcfe2a, resulting in the production of E2AER fusion proteins. The use of tamoxifen inducible ER fusion proteins in mouse genetics has already been established as a valuable tool, especially with the vast use of the Cre recombinase-ER fusion protein for inducible gene knockout in mice [12-15]. In addition, ER fusion with a variety of transcription factors has also been successfully employed for analysis of gene expression. For example, MyoD-ER fusion proteins have been expressed by viral transduction in mouse embryonic fibroblasts for in vitro study of MyoD gene regulation [16] and in mouse fibroblasts for analysis of MyoD activation in vivo post transplantation of transduced cells into recipient animals [17]. However, we do not know how useful the ER system will be in live animals when targeting an endogenous locus. Our E2AER system now introduces an ER fusion with a bHLH transcription factor into the mouse genome for analysis of an endogenously expressed protein.
###end p 11
###begin p 12
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 15 21 15 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 317 323 317 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 256 261 <span type="species:ncbi:10090">mouse</span>
E2AER/+ and E2AER/ER mice, along with E2AER protein function, are analyzed here in the context of B cell development. A block in B cell development at the pre-proB cell stage, prior to B lineage commitment, has been characterized by previous E2A-deficient mouse models [18,19]. A rescue in B cell development from E2AER/ER pre-proB cells upon tamoxifen treatment would be a stringent test to verify inducible E2AER function.
###end p 12
###begin p 13
###xml 65 68 65 68 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 291 297 291 297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 338 345 338 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 440 446 440 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 467 475 467 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 501 504 501 504 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 504 512 504 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 297 301 <span type="species:ncbi:10090">mice</span>
In this study, we provide the initial characterization of the E2AER system. E2AER protein activity was rapidly induced upon tamoxifen treatment and reversibly regulated by tamoxifen withdrawal. Even though we show effective induction of E2AER DNA binding activity, tamoxifen treatment of E2AER/ER mice did not efficiently restore B cells in vivo. However, tamoxifen treatment was able to rescue and support early B cell development from E2AER/ER pre-proB cells in an ex vivo culture system. Use of E2AER ex vivo culture systems may therefore be beneficial for the study of gene regulation in B cells and other E2A-regulated cell lineages.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 21 24 21 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
Generation of the E2AER allele
###end title 15
###begin p 16
###xml 3 8 3 8 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 15 21 15 21 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 212 219 212 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a </italic>
###xml 237 240 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 255 260 255 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A, B</xref>
###xml 325 329 325 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP </sup>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 417 424 417 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a </italic>
###xml 516 519 516 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 806 812 806 812 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm </sup>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1071 1083 1071 1083 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm/E47bm </sup>
###xml 1217 1223 1217 1223 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 1301 1302 1301 1302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1399 1402 1399 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 1613 1616 1613 1616 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 21 25 <span type="species:ncbi:10090">mice</span>
###xml 162 167 <span type="species:ncbi:10090">mouse</span>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 998 1002 <span type="species:ncbi:10090">mice</span>
###xml 1083 1087 <span type="species:ncbi:10090">mice</span>
E2AER/+ and E2AER/ER mice were generated by using a knock-in strategy for tamoxifen-inducible E2A function. The tamoxifen-responsive ligand binding domain of the mouse ER [20] was inserted at the carboxyl end of tcfe2a to produce the E2AER allele (Figure 1A, B). With this targeting strategy, similar to that used for the E2AGFP strain previously developed in our lab [21], both alternatively spliced products of the tcfe2a gene, E12 and E47, are translated as ER fusion proteins. Initial characterization of the E2AER allele indicated normal expression levels of E2A mRNA in the presence of the ER insertion (Figure 1C). Previous study of E2A knockout mice has demonstrated stunted growth and a high lethality rate of homozygous animals within the first few weeks after birth [18,19]. In contrast, the E2AE47bm strain, expressing a dominant negative form of E47, was originally described as indistinguishable from wild-type litter mates in size and survival [22]. However, this work was analyzing mice on a mixed genetic background. Upon backcrossing to C57BL/6, the E2AE47bm/E47bm mice became smaller in size and demonstrated the high lethality rate like that shown with the knockout animals (unpublished data). E2AER/ER animals also exhibit stunted growth and reduced survival (see Additional file 1). Fortunately, the lethality rate in our experience has been less severe in litters from the E2AER strain than that observed with our E2A knockout and dominant negative strains. However, we do not know if this slight increase in postnatal survival is due to the presence of the E2AER protein or because our E2AER strain is currently on a mixed background.
###end p 16
###begin p 17
###xml 21 24 21 24 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Generation of the E2A<sup>ER </sup>allele</bold>
###xml 80 85 80 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 92 98 92 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 131 138 131 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">tcfe2a </italic>
###xml 483 486 483 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 491 495 491 495 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+</sup>
###xml 504 510 504 510 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 669 672 669 672 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 677 681 677 681 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+</sup>
###xml 690 696 690 696 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 98 102 <span type="species:ncbi:10090">mice</span>
###xml 125 130 <span type="species:ncbi:10090">mouse</span>
Generation of the E2AER allele. (A) Targeting strategy for the generation of E2AER/+ and E2AER/ER mice. The 3' region of the mouse tcfe2a gene was used for targeting. Gene direction, the E47, E12, and 3' exons (gray boxes), and inserted tamoxifen-responsive estrogen receptor ligand binding domain (ER, black box) are shown. Regions mediating homologous recombination are denoted by dotted lines. The selection markers pgkneo and pgktk are located as shown. (B) Genotyping PCR of E2A+/+, E2AER/+, and E2AER/ER DNA using primers yz164, yz29, and bjE2Ar3 as shown in (A), that yield a 0.9 kb wild-type allele and 1.2 kb mutant allele. (C) RT-PCR of cDNA acquired from E2A+/+, E2AER/+, and E2AER/ER thymus RNA. E2A and GAPDH (control) expression was detected by semi-quantitative PCR of 5-fold serial dilutions.
###end p 17
###begin title 18
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
The E2AER allele resembles an E2A-deficient allele in the absence of ligand
###end title 18
###begin p 19
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 599 601 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 602 604 602 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 625 629 625 629 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP </sup>
###xml 736 737 736 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1007 1008 1007 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
B cells develop from hematopoietic stem cells (HSC) in the bone marrow through a series of developmental stages [23]. The pre-proB cell stage is an intermediate stage as lymphoid progenitors develop into committed proB cells. Pre-proB cells can be characterized by the expression of B220 and CD43 and the absence of CD19 expression. As pre-proB cells transition to the proB cell stage, CD19 expression is induced and cells undergo commitment to the B cell lineage. E2A is critical for this transition, as demonstrated by the block in development at the pre-proB cell stage in E2A-deficient animals [18,19,24]. Analysis of E2AGFP mice displays the up-regulation of E2A protein levels from the pre-proB to proB stage (see Additional file 2) [21]. This increase in E2A expression is likely critical for E2A's regulation of the B cell lineage gene expression profile given the importance of E2A gene dosage. For example, elimination of one copy of E2A has been shown to greatly reduce the number of proB cells [4,18].
###end p 19
###begin p 20
###xml 42 48 42 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 140 152 140 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm/E47bm </sup>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 231 233 231 233 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 266 272 266 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 419 421 419 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 509 511 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 515 517 515 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 622 628 622 628 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 668 669 668 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 272 276 <span type="species:ncbi:10090">mice</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
Investigation of B cell development in E2AER/ER mice revealed a block at the pre-proB cell stage, similar to that seen in the E2A-mutant E2AE47bm/E47bm mice (Figure 2A) [22]. Occasionally we have observed a small population of CD19+ B cells in the bone marrow of E2AER/ER mice, but these incidences of leaky B cell development did not appear to produce a significant population of mature, Ig expressing B cells (Figure 2B). Even though E2A has been suggested to influence proliferation in developing B cells [20,25-27], no significant difference in expansion at the pre-proB cell stage was observed by BrdU analysis of E2AER/ER and wild-type mice (see Additional file 3).
###end p 20
###begin p 21
###xml 60 66 60 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 0 70 0 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink">B cell developmental block at the pre-proB cell stage in E2A<sup>ER/ER </sup>mice</bold>
###xml 129 132 129 132 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 137 141 137 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+</sup>
###xml 146 151 146 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER</sup>
###xml 156 163 156 163 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm/+</sup>
###xml 172 184 172 184 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm/E47bm </sup>
###xml 217 219 217 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 299 300 299 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 304 306 304 306 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 380 381 380 381 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 447 449 447 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 482 488 482 488 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 526 532 526 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 539 543 539 543 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 621 623 621 623 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 668 669 668 669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 673 675 673 675 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 66 70 <span type="species:ncbi:10090">mice</span>
###xml 184 188 <span type="species:ncbi:10090">mice</span>
###xml 488 492 <span type="species:ncbi:10090">mice</span>
###xml 543 547 <span type="species:ncbi:10090">mice</span>
B cell developmental block at the pre-proB cell stage in E2AER/ER mice. (A) Representative staining of bone marrow cells from E2A+/+, E2AER/+, E2AER/ER, E2AE47bm/+, and E2AE47bm/E47bm mice. Cells are pre-gated on 7AAD- lymphocytes and relative percentages are given in each plot. Cells from the CD43+B220+ gate are displayed in histograms analyzing CD19 expression. Pre-proB (CD19-) and proB (CD19+) cell percentages are shown. (B) Occasional CD19+ B cell population detected in E2AER/ER mice. Staining of bone marrow from E2AER/ER and E2A+/+ mice for B220, CD43, CD19, and IgM expression. All plots are pre-gated on 7AAD- lymphocytes. Histograms are pre-gated on B220+CD43+ cells as above and relative percentages are shown.
###end p 21
###begin p 22
###xml 125 130 125 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 137 143 137 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 254 259 254 259 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 266 272 266 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 381 385 381 385 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 392 398 392 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 420 425 420 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 704 710 704 710 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 943 945 942 944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 1049 1052 1048 1051 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 1052 1057 <span type="species:ncbi:10090">mouse</span>
For analysis of E2AER protein expression and DNA binding activity, we chose to derive Abelson transformed preB cells from E2AER/+ and E2AER/ER bone marrow [28]. E2AER protein expression was verified by Western Blot analysis of whole cell lysates from E2AER/+ and E2AER/ER Abelson cells (Figure 3A). While E2AER protein levels appeared similar to wild-type levels when comparing E2A+/+ and E2AER/ER cells, analysis of E2AER/+ cells suggested that E2AER protein expression may be lower than wild-type. Protein analysis of tamoxifen treated cells displayed similar results, indicating that the relative E2AER protein levels are not affected by the presence or absence of tamoxifen. Nuclear extracts from E2AER/ER Abelson cells were then used to conduct electrophoretic gel shift analysis of E2AER binding to an E2A binding sequence, muE5. In the absence of tamoxifen treatment, no DNA binding activity was observed from the E2AER protein (Figure 3B). Together, the block in B cell development and lack of E2AER DNA binding activity suggest that the E2AER mouse model functions as an E2A-deficient system in the absence of ligand.
###end p 22
###begin p 23
###xml 0 65 0 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Induction and reversible regulation of E2AER DNA binding activity</bold>
###xml 141 144 141 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 149 152 149 152 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 157 161 157 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+</sup>
###xml 166 171 166 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER</sup>
###xml 180 188 180 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP/GFP </sup>
###xml 311 314 311 314 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 319 323 319 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+</sup>
###xml 332 338 332 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 422 425 422 425 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+</sup>
###xml 430 437 430 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP/GFP</sup>
###xml 446 450 446 450 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 607 613 607 613 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
Induction and reversible regulation of E2AER DNA binding activity. (A) Detection of E2AER protein. Whole cell lysates were collected from E2A+/+, E2A-/-, E2AER/+, E2AER/ER, and E2AGFP/GFP Abelson-transformed preB cell lines and analyzed by Western Blot for E2A protein expression using an anti-E2A antibody. E2A+/+, E2AER/+, and E2AER/ER Abelson cells were also cultured with tamoxifen prior to analysis, as indicated. E2A+/+, E2AGFP/GFP, and E2A-/- lines were used as positive and negative controls for E2A proteins. ERK2 was used as a loading control. (B and C) Analysis of E2AER DNA binding activity. E2AER/ER Abelson-transformed preB cells were cultured (B) without and with tamoxifen for 1, 6 and 10 hr and (C) with tamoxifen and upon tamoxifen withdrawal for 1 and 6 hr. Nuclear extracts were analyzed by gel shift for E2A DNA-binding using a muE5 probe. Anti-E2A antibody was used to demonstrate specificity (Ab). E2A-DNA complexes (arrow) and antibody-shifted complexes (arrow head) are indicated. *Non-specific band.
###end p 23
###begin title 24
Rapid activation and reversible regulation of E2AER activity
###end title 24
###begin p 25
###xml 26 32 26 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 533 535 532 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 634 637 633 636 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
Tamoxifen treatment of E2AER/ER Abelson cells resulted in rapid E2AER DNA binding activity within 1 hr of treatment (Figure 3B). The specificity of the protein binding to the muE5 probe was verified by using an anti-E2A antibody that effectively super-shifted the protein/DNA complex. The effect of tamoxifen withdrawal was then tested by washing tamoxifen-treated cells and growing them in the absence of tamoxifen for 1 and 6 hr time points. Loss of E2AER DNA binding activity was seen within 6 hrs of tamoxifen withdrawal (Figure 3C), indicating relatively fast reversibility of E2A function. These results demonstrate that the E2AER model can be used not only as an inducible model, but this system may also be valuable for providing a tightly regulated window of E2A activity.
###end p 25
###begin title 26
###xml 62 69 62 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo</italic>
Induction of E2AER activity supports early B cell development ex vivo
###end title 26
###begin p 27
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 95 101 95 101 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 184 192 184 192 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 650 658 650 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 798 803 798 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A, B</xref>
###xml 967 974 966 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 101 105 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
We first tested for a functional outcome of E2A induction by in vivo tamoxifen treatment of E2AER/ER mice followed by analysis of B cell populations in the bone marrow and spleen. All in vivo treatment efforts, including intraperitoneal injection and treatment in drinking water, unfortunately resulted in low efficiency rescue of B cell development. The emergence of B cells in tamoxifen-treated animals was rarely great enough to determine if the resulting B cells were generated in response to the tamoxifen treatment or were simply the incidence of leaky B cell development described above. The most significant recovery of B cells observed from in vivo treatment, which resulted from a 27 day tamoxifen treatment, was still considerably less than the B cell population in control mice (Figure 4A, B). However, the presence of Ig mu heavy chain (IgM) positive B cells in the spleen does suggest that a low level of tamoxifen-dependent B cell development occurred in vivo.
###end p 27
###begin p 28
###xml 46 54 46 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 80 86 80 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Inefficient rescue of B cell development upon <italic>in vivo </italic>tamoxifen treatment of E2A<sup>ER/ER </sup>mice</bold>
###xml 113 118 113 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 125 131 125 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 281 283 281 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 328 329 328 329 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 333 335 333 335 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 454 459 454 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 466 472 466 472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 86 90 <span type="species:ncbi:10090">mice</span>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 472 476 <span type="species:ncbi:10090">mice</span>
Inefficient rescue of B cell development upon in vivo tamoxifen treatment of E2AER/ER mice. (A) Two month old E2AER/+ and E2AER/ER control mice were treated with tamoxifen in their drinking water for 27 days. Indicated tissues were stained as shown. All plots are pre-gated on 7AAD- lymphocytes. Histograms are pre-gated on B220+CD43+ cells as shown. Relative percentages are displayed. (B) Representative spleen staining from age-matched non-treated E2AER/+ and E2AER/ER mice.
###end p 28
###begin p 29
###xml 15 23 15 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 60 68 60 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 133 135 133 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 154 160 154 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 311 317 311 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 371 373 371 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 437 443 437 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 487 489 487 489 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 586 592 586 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1016 1022 1016 1022 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 1098 1100 1098 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
In contrast to in vivo tamoxifen treatment, treatment in an ex vivo B cell culture system effectively rescued the development of CD19+ B cells. Sorted E2AER/ER pre-proB cells were cultured in hormone-free media on an S17 stromal layer in the presence of IL-7, with or without tamoxifen. Control DMSO treated E2AER/ER pre-proB cells failed to develop efficiently into CD19+ B cells over the course of 5 days, whereas tamoxifen treated E2AER/ER pre-proB cells effectively gave rise to CD19+ B cells (Figure 5A). Interestingly, the kinetics of B cell development from tamoxifen treated E2AER/ER pre-proB cells appeared delayed compared to that of control cells. In addition to using CD19 expression to validate the rescue of B cell development, we analyzed Pax5 expression throughout the 5 day culture. Pax5, initiated downstream of E2A expression, is a transcription factor critical for B cell lineage commitment [29]. Consistent with CD19 expression, induction of Pax5 expression was observed in tamoxifen treated E2AER/ER pre-proB cells, also appearing delayed compared to control cultures (Figure 5B).
###end p 29
###begin p 30
###xml 56 62 56 62 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 0 76 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Tamoxifen treatment restores B cell development from E2A<sup>ER/ER </sup>pre-proB cells</bold>
###xml 88 93 88 93 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 100 106 100 106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 289 291 289 291 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 320 322 320 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Tamoxifen treatment restores B cell development from E2AER/ER pre-proB cells. Sorted E2AER/+ and E2AER/ER pre-proB cells were plated in hormone-free media on S17 stromal cells on Day 0 in the presence of IL-7 with tamoxifen or DMSO (untreated control). (A) Cells are pre-gated on 7AAD-B220+ lymphocytes. Percents of CD19+ cells on Day 1, 3, and 5 are displayed. Data are representative of 4 independent experiments. (B) Expression of Pax5 was analyzed by quantitative RT-PCR from RNA collected from Day 1, 3, and 5 cultures shown in (A). Samples were normalized to the expression of GAPDH. Graphed results are means from triplicate runs (n = 3) with error bars representing standard error of the mean (SEM).
###end p 30
###begin p 31
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 133 135 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 344 345 344 345 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 455 456 455 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 945 951 945 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 965 966 965 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 1116 1122 1116 1122 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 1167 1169 1167 1169 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1268 1269 1268 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 641 645 <span type="species:ncbi:10090">mice</span>
###xml 717 721 <span type="species:ncbi:10090">mice</span>
Another key event during early B cell development, downstream of E2A function, is rearrangement of the Ig heavy chain locus (IgH) [2,18,19]. We next used this culture system to determine if induction of E2AER activity could also support IgH V to DJ recombination. To amplify V to DJ rearrangements, we chose primers recognizing members of the VH1 gene family [30], which represent a large percentage of the total IgH V genes, and primers recognizing the JH4 gene segment. Rearrangements were analyzed in Day 8 cultured samples because we did not observe consistent V to DJ PCR signals until this point in the time course analysis. Wild-type mice were used as positive controls for detecting recombination events, and mice deficient in the recombination activating gene RAG1, required for V(D)J recombination, were used as negative controls. Analysis of Day 8 cultures demonstrated a clear V to DJ rearrangement product from tamoxifen treated E2AER/ER cells (Figure 6). V to DJ rearrangement was further verified by sequencing analysis (see Additional file 4). The faint product detected from DMSO control treated E2AER/ER cells was accompanied by a small "leaky" CD19+ population generated at this relatively late time point in the culture system (see Additional file 5). However, only one unique rearrangement product was identified out of all of the colonies sequenced for this sample. In addition to providing functional proof of induced E2A activity, the detection of IgH recombination, along with the induction of CD19 and Pax5 expression described above, suggests that restored E2A function can rescue B cell development from the pre-proB cell stage.
###end p 31
###begin p 32
###xml 64 70 64 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">IgH recombination detected upon culture of tamoxifen treated E2A<sup>ER/ER </sup>pre-proB cells</bold>
###xml 174 178 174 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 191 197 191 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 224 225 224 225 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 232 233 232 233 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 383 384 383 384 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 412 413 412 413 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 535 536 535 536 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
IgH recombination detected upon culture of tamoxifen treated E2AER/ER pre-proB cells. DNA was analyzed for IgH V to DJ rearrangements from Day 8 cultured wild-type (WT), Rag1-/- (Rag) and E2AER/ER (ER) pre-proB cells using VH1 and JH4 primers. Cells were cultured in hormone-free media on S17 stromal cells with IL-7 and tamoxifen (T) or DMSO (D). V-DJ rearrangement products using VH1 family gene segments and JH4 are shown. WT and Rag were used as positive and negative controls, respectively. No products were detected when using dH2O as an additional negative control (data not shown). CD14 was used to demonstrate DNA loading. This result is representative of 4 independent nested PCR reactions.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 550 553 550 553 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
The E2AER system provides an improved method for analyzing E2A function. Previous analysis using over-expression of E2AER fusion proteins by retroviral transduction has already demonstrated the value of inducible E2A activity [20,31-34]. However, toxicity is often a problem with high levels of E2A in the cell [20,35], and viral transduction is not ideal for all cell types. In addition, the changes in gene expression detected upon over-expression of E2A may not always be representative of endogenous E2A function. Therefore, generation of the E2AER allele provides an attractive system for studying gene regulation and other E2A-regulated events in potentially any E2A-expressing cell type at a more physiological level.
###end p 34
###begin p 35
###xml 296 304 296 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 410 416 410 416 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 532 538 532 538 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 598 604 598 604 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 971 973 971 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 974 976 974 976 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 977 979 977 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1207 1213 1207 1213 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 1360 1365 1360 1365 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 1387 1389 1387 1389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 1887 1891 1887 1891 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 1898 1904 1898 1904 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 1959 1965 1959 1965 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 2045 2047 2045 2047 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Here we demonstrate the rapid induction of E2AER DNA binding activity upon tamoxifen treatment and its potential for reversible function upon tamoxifen withdrawal. The ability to tightly control E2A activity allows for kinetic analysis of downstream events. Analysis of B cell development in our ex vivo culture system demonstrated a rescue from the pre-proB cell stage, but suggested delayed kinetics from E2AER/ER pre-proB cells compared to B cell development from control pre-proB cells. This result suggests that even though E2AER/ER and wild-type pre-proB cells are phenotypically similar, E2AER/ER pre-proB cells may not have equivalent developmental potential or may require additional cellular changes prior to entering the B cell lineage. It is possible that E2A-regulated events normally occurring earlier in development, as suggested in hematopoietic stem cell (HSC), lymphoid-primed multipotent progenitor (LMPP), and common lymphoid progenitor (CLP) stages [27,36,37], were occurring upon restored E2A function in pre-proB cells and requiring these cells to "catch up" with their wild-type counterparts prior to progressing to the next stage. Alternatively, the developing tamoxifen-treated E2AER/ER B cells may not have expanded as rapidly as wild-type cells upon commitment to the B cell lineage. Our Western Blot analysis of E2A proteins in E2AER/+ Abelson cells (Figure 3A) suggested that the E2AER protein level may also have been contributing to the delayed kinetics. In this sample, the E2AER band appeared less intense than the wild-type E2A band. However, it is not possible to determine from this analysis if the lower intensity was a result of reduced protein levels or variation in antibody affinity for the E2AER versus wild-type E2A protein. In addition, there was not a striking difference between the E2AER and wild-type protein levels when comparing the E2A+/+ and E2AER/ER samples. Further investigation of tamoxifen treated E2AER/ER pre-proB cells will be necessary to understand why the delayed detection of CD19+ B cells was observed.
###end p 35
###begin p 36
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 190 196 190 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 425 433 425 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S5">5</xref>
###xml 635 641 635 641 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 644 646 644 646 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 661 669 661 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 698 700 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 948 954 948 954 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
Our ex vivo culture data clearly indicated a rescue of early B cell development to the proB cell stage. However, we have so far been unable to determine if tamoxifen treatment can rescue E2AER/ER B cells through the subsequent preB cell stage, when E2A is known to be critical for Ig kappa light chain (Igk) recombination [38]. We were unable to test for induction of Igk recombination or surface IgM expression by using our ex vivo culture system because this system primarily supports development at a stage prior to these events (see Additional file 5 and data not shown). The presence of the small, but increased, population of E2AER/ER IgM+ B cells in the in vivo treatment experiment (Figure 4A) is the only current evidence suggesting tamoxifen-induced E2AER activity may be able to rescue B cell development to maturity. Additional B cell culture systems would be necessary to determine if tamoxifen treatment can rescue later stages of E2AER/ER B cell development.
###end p 36
###begin p 37
###xml 6 14 6 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 86 94 86 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 226 234 226 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 385 387 385 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 388 390 388 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 473 481 473 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 579 585 579 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
While in vivo tamoxifen treatment was not efficient for restoring B cell development, in vivo treatment may still be useful for analysis of E2A function in other cell lineages. We suggest two reasons for ineffective rescue of in vivo B cell development. First, progression through several stages of lymphocyte development is known to be dependent on proper E-protein dosage [4,6,18,26,39,40], and it is possible that the required E2A threshold is not maintained during our in vivo treatment for rescue of B cell development. For example, as mentioned above, we do not know if E2AER/ER cells can sufficiently progress through the preB cell stage of development. Second, E2A has been suggested to be important for B cell survival [41]. Therefore, it is conceivable that even if B cells are rescued by tamoxifen treatment, they may be lost if E2AER activity is not maintained throughout the treatment.
###end p 37
###begin p 38
###xml 7 10 7 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 301 302 301 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 303 304 303 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 406 412 406 412 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 268 272 <span type="species:ncbi:10090">mice</span>
###xml 366 370 <span type="species:ncbi:10090">mice</span>
###xml 412 416 <span type="species:ncbi:10090">mice</span>
The E2AER system may instead be more valuable for in vivo study of T cell development, or other lineages expressing multiple E-protein family members. Since E-proteins demonstrate many redundant functions, T cell development is not completely blocked in E2A-deficient mice due to the presence of HEB [4,6,42,43]. Because T cells are fully developed in E2A-deficient mice, in vivo tamoxifen treatment of E2AER/ER mice may be more valuable for the study of E2A function during T cell development.
###end p 38
###begin p 39
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 311 317 311 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 499 505 499 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 722 731 722 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 782 785 782 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 785 793 785 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 505 509 <span type="species:ncbi:10090">mice</span>
There are many additional applications for the E2AER system. In addition to advantages in speed, expression level, and reversibility, this inducible system may allow analysis of E2A function in specific cell stages that have been difficult to analyze in previous E2A-deficient models. Tamoxifen treatment of E2AER/ER cells may be valuable by allowing progression to developmental stages that are absent in E2A-deficient animals or affected due to the lack of E2A at earlier developmental stages. E2AER/ER mice also provide a useful tool for studying changes in E2A function with age or for analyzing E-protein function in combination with other genetic models. Given the rapid induction of E2AER DNA binding activity upon in vitro tamoxifen treatment, we believe that the use of E2AER ex vivo culture systems may be most valuable, especially for identifying new E2A targets and studying the kinetics of E2A gene regulation.
###end p 39
###begin title 40
Conclusion
###end title 40
###begin p 41
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 378 384 378 384 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 526 534 526 534 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 560 565 560 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER</sup>
###xml 594 602 594 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 719 722 719 722 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 819 827 819 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 384 388 <span type="species:ncbi:10090">mice</span>
We have established a new genetic model by generating the E2AER allele. This model allows for inducible function of E2A, a transcription factor displaying an extensive range of functions across multiple developmental programs. E2AER activity is rapidly induced at the protein level upon tamoxifen treatment and is reversible upon tamoxifen withdrawal. Tamoxifen treatment of E2AER/ER mice was, however, unable to efficiently restore wild-type levels of B cells. The functionality of E2AER was instead successfully verified by ex vivo tamoxifen treatment of E2AER/ER B cell progenitors. In this ex vivo culture system, induced E2AER protein function was able to rescue and support early B cell development. Thus, the E2AER model provides an attractive system to regulate and study E2A protein function, especially under ex vivo conditions where cells can gain sustained access to high levels of tamoxifen.
###end p 41
###begin title 42
Methods
###end title 42
###begin title 43
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 43
###begin p 44
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">E47bm </sup>
###xml 46 48 46 48 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 72 75 72 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER </sup>
###xml 9 13 <span type="species:ncbi:10090">mice</span>
###xml 120 124 <span type="species:ncbi:10090">mice</span>
E2AE47bm mice have been described previously [22]. Generation of the E2AER allele is described below. All research with mice was performed in accordance with relevant guidelines, and protocols were approved by the Duke University Animal Care and Use Committee.
###end p 44
###begin title 45
Generation of the E2AER allele
###end title 45
###begin p 46
###xml 93 97 93 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP </sup>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 866 871 866 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/+ </sup>
###xml 878 884 878 884 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
###xml 727 732 <span type="species:ncbi:10090">Mouse</span>
###xml 884 888 <span type="species:ncbi:10090">mice</span>
The gene targeting strategy used was a modification of the strategy for generation of the E2AGFP strain [21]. The tamoxifen-responsive region of the mouse estrogen receptor ligand binding domain containing the G525R mutation [44] was PCR amplified from the MigR1-E47R vector [20] using the primers ERfpA: 5'-CGGATCCACGAAATGAAATGGGTGC-3' and ERrpA: 5'-CCGGCCGCTAGAATTCGATCGTGTTGGGGAAGCCCTC-3' to introduce a 5' BamHI site and 3' EcoRI and EagI sites for subsequent cloning steps. The ER fragment was inserted, replacing EGFP, at the BamHI position in frame with E2A. The targeting construct also contained a positive selection marker, PGKNeo cassette, and a negative selection marker, PGK driven thymidine kinase (TK) cassette. Mouse ES cells used were derived from a 129/sv strain obtained from Phillippe Soriano's lab in 1995 and then maintained in our own lab. E2AER/+ and E2AER/ER mice were maintained on a C57BL6 and 129/sv mixed background. Three primers were used for detection of wild-type and mutant alleles, yz164: 5'-AAGAACGAGGCCTTCCGTGTC-3', yz29: 5'-TCGCAGCGCATCGCCTTCTA-3', and bjE2Ar3: 5'-CAAGAGACTAGGATGCCACTG-3'.
###end p 46
###begin title 47
RT-PCR
###end title 47
###begin p 48
###xml 92 94 92 94 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
RNA extraction, DNase I treatment and reverse transcription have been described previously [41]. Quantitative real-time PCR analysis for Pax5 expression was performed using a Roche LightCycler and Fast-Start DNA master SYBR green kit I (Roche) as per manufacturer's instructions. The following primers were used, E2A: f1 5'-CCAGTCTCAGAGAATGGCAC-3' and r1 5'-CCTTCGCTGTATGTCCGGCTAG-3'; Pax5 and GAPDH primers [41].
###end p 48
###begin title 49
Cell staining and flow-cytometry
###end title 49
###begin p 50
###xml 367 368 367 368 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 372 373 372 373 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 377 378 377 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
For sorting, bone marrow was harvested and pooled from 2-3 mice per genotype. Cells positive for lineage markers Mac-1, Gr-1, Ter-119, and CD3 were depleted with Dynal Dynabeads (Invitrogen) according to manufacturer's instructions. Dead cells stained with 7-aminoactinomycin D (7AAD, Molecular Probes) were excluded. Pre-proB cells were further distinguished as B220+CD43+CD19-. FACS analysis was done with a FACSCalibur (BD Biosciences) or FACSVantage SE with DiVa option (BD Biosciences) and FlowJo software (Tree Star). FACSVantage SE with DiVa option was used for cell sorting.
###end p 50
###begin title 51
###xml 26 35 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
Tamoxifen preparation for in vitro culture treatment
###end title 51
###begin p 52
Tamoxifen (Sigma) was prepared as a 1 mM stock (1000x) dissolved in cell culture grade dimethyl sulfoxide (DMSO) and stored at -20degreesC.
###end p 52
###begin title 53
Abelson transformed preB cells
###end title 53
###begin p 54
###xml 7 13 7 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 128 133 128 133 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER</sup>
###xml 679 685 679 685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 938 940 938 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 59 65 <span type="species:ncbi:10090">Murine</span>
###xml 134 139 <span type="species:ncbi:10090">mouse</span>
The E2AER/ER Abelson preB cell line was derived by Abelson Murine Leukemia Virus transformation of bone marrow cells from an E2AER/ER mouse. Briefly, whole bone marrow was plated on an S17 stromal layer in the presence of 1 uM tamoxifen and 10 ng/mL IL-7 in 5% FBS RMPI media. This culture was performed prior to transduction to ensure cells were proliferating and were at the optimal target stage for Abelson transformation. Once an expanding B cell population was observed, cells were infected with Abelson virus in the presence of 4 ug/mL polybrene. Abelson transformed cells were then removed from the stromal layer, and tamoxifen and IL-7 were withdrawn. The established E2AER/ER Abelson preB cell line was maintained in 10% FBS RPMI media (also containing 100 units/ml penicillin, 100 ug/mL streptomycin and 55 uM 2-mercaptoethanol) prior to experimental analysis. Additional Abelson lines were established as described previously [32].
###end p 54
###begin title 55
Western Blot
###end title 55
###begin p 56
Abelson preB cell lines were cultured without tamoxifen or with 1 uM tamoxifen for 24 hr prior to analysis. Cells were lysed in RIPA lysis buffer (1% Triton, 0.5% sodium deoxycholic acid, 0.1% SDS, 25 mM Tris-Cl pH 7.6, 150 mM NaCl, 5 mM EDTA) with protease inhibitors. Whole cell lysates were resolved by SDS-PAGE and blotted with anti-E2A (G127-32, BD Biosciences, 554077) and anti-ERK2 (C-14, Santa Cruz Biotechnology, sc-154) antibodies.
###end p 56
###begin title 57
Electrophoretic mobility shift assay
###end title 57
###begin p 58
###xml 3 9 3 9 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">32</sup>
E2AER/ER Abelson preB cells were cultured with or without 1 uM tamoxifen as indicated. For withdrawal analysis, tamoxifen-treated cells were washed and re-plated in the absence of tamoxifen for the indicated times. Nuclear extracts were incubated with a 32P-labeled muE5 oligonucleotide probe, with or without Yae anti-E2A monoclonal antibody (Santa Cruz Biotechnology, sc-416), and resolved on a 5% polyacrylamide gel. Gels were dried and exposed to a phosphor screen for phosphorimager analysis (Amersham Biosciences). Oligos used for muE5 probe: 5'-TCGAAGAACACCTGCAGCAGCT-3' and 5'-TAGAGCTGCTGCAGGTGTTCTT-3'.
###end p 58
###begin title 59
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
In vivo tamoxifen treatment
###end title 59
###begin p 60
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice were treated with tamoxifen in the drinking water for 27 days. A 68 mg/mL tamoxifen in ethanol stock was used to bring the concentration in drinking water to approximately 26 ug/mL, resulting in 0.04% ethanol in water. A fresh bottle of tamoxifen water was given every 5 days.
###end p 60
###begin title 61
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ex vivo </italic>
Ex vivo pre-proB culture system
###end title 61
###begin p 62
###xml 101 103 101 103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">4 </sup>
Sorted pre-proB cells were plated on an S17 stromal layer in 24-well plates at approximately 1.5 x 104 cells per well and cultured with 5% FBS RPMI hormone-free media containing 10 ng/mL IL-7. Hormone free media consisted of phenol-red free RPMI 1640 supplemented with 5% charcoal/dextran treated FBS (Hyclone), 100 units/mL penicillin, 100 ug/mL streptomycin, and 55 uM 2-mercaptoethanol. Treated wells contained 1 uM tamoxifen and untreated controls were given DMSO alone (0.1%). Cells received fresh media, cytokine, and tamoxifen or DMSO every other day. Cells were harvested at time points indicated, and samples were split in half for FACS analysis and RNA or DNA extraction.
###end p 62
###begin title 63
IgH rearrangement analysis
###end title 63
###begin p 64
###xml 27 35 27 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ex vivo </italic>
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 178 179 178 179 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 338 339 338 339 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 382 383 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 445 446 445 446 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 482 484 482 484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 491 492 491 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 535 537 535 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 620 621 620 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 624 625 624 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 626 627 626 627 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
Sorted pre-proB cells were ex vivo cultured as described above. DNA was extracted from Day 8 cultures and then analyzed for IgH V to DJ rearrangements using VH1 gene family and JH4 specific primers. A nested PCR strategy was used to amplify rearrangements involving VH1 family gene segments. The following primers were used for Round 1: VH1 ext 5'-AGRTYCAGCTGCARCAGTCT-3' [30] and JH4 YZB6 5'-TCCCTCAAATGAGCCTCCAAAGTCC-3' [45] and for Round 2: VH1 int 5'-GARGATRTCCTGYAAGGCTTC -3' [30] and JH4 YZB5 5'-CCTGAGGAGACGGTGACTGAGGTTCCTTG-3'[46]. CD14 primers were used to demonstrate the presence of DNA in all samples [41]. VH1-DHJH4 PCR products were cloned into a pCR4 TOPO vector (Invitrogen) and sequenced (Direct Sequencing from Colonies Service, Eton Bioscience, Inc). Rearrangement product sequences were analyzed by SoDA [47].
###end p 64
###begin title 65
Authors' contributions
###end title 65
###begin p 66
MEJ participated in the design of the study, carried out the studies, and drafted the manuscript. MK participated in the design of the study and assisted with cell sorting. YZ conceived of the study and participated in its design. All authors read and approved the final manuscript.
###end p 66
###begin title 67
Supplementary Material
###end title 67
###begin title 68
Additional file 1
###end title 68
###begin p 69
###xml 0 42 0 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Characterization of E2A gene-targeted mice</bold>
###xml 38 42 <span type="species:ncbi:10090">mice</span>
Characterization of E2A gene-targeted mice. Phenotypes are descriptive of homozygous animals.
###end p 69
###begin p 70
Click here for file
###end p 70
###begin title 71
Additional file 2
###end title 71
###begin p 72
###xml 0 82 0 82 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Up-regulation of E2A protein levels during pre-proB to proB cell stage development</bold>
###xml 91 95 91 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP </sup>
###xml 235 243 235 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP/GFP </sup>
###xml 250 254 250 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 398 402 398 402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 406 407 406 407 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 411 413 411 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 453 461 453 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink">GFP/GFP </sup>
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 480 481 480 481 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 485 486 485 486 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 502 503 502 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 507 508 507 508 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 512 513 512 513 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
Up-regulation of E2A protein levels during pre-proB to proB cell stage development. (A) E2AGFP allele. An E2A-GFP fusion protein is produced from this allele. Therefore, GFP expression can be used to monitor E2A protein levels. (B) E2AGFP/GFP and E2A+/+ control bone marrow was stained for B220, CD43, and CD19 surface expression. Cells are pre-gated on lymphocytes. GFP expression is shown for E2A+/+ B220+CD43+ (pre-proB + proB) control cells, and E2AGFP/GFP pre-proB (B220+CD43+CD19-) and proB (B220+CD43+CD19+) compartments.
###end p 72
###begin p 73
Click here for file
###end p 73
###begin title 74
Additional file 3
###end title 74
###begin p 75
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">In vivo </italic>
###xml 55 61 55 61 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 91 95 91 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 0 109 0 109 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>In vivo </italic>BrdU labeling suggests similar expansion of E2A<sup>ER/ER </sup>pre-proB cells compared to E2A<sup>+/+ </sup>pre-proB cells</bold>
###xml 143 149 143 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 156 160 156 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 490 492 490 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 534 535 534 535 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 539 540 539 540 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 544 545 544 545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 565 571 565 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 693 694 693 694 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 698 699 698 699 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 728 732 728 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 115 119 <span type="species:ncbi:10090">mice</span>
###xml 571 576 <span type="species:ncbi:10090">mouse</span>
In vivo BrdU labeling suggests similar expansion of E2AER/ER pre-proB cells compared to E2A+/+ pre-proB cells. Two mice from each genotype, E2AER/ER and E2A+/+ control, were IP injected with 1 mg BrdU and analyzed 4 hrs post injection. Bone marrow was stained for B220, CD43, and CD19 surface expression, then processed to analyze BrdU labeling with a FITC BrdU Flow Kit as per manufacturer's instructions (BD Pharmingen). All plots are pre-gated on lymphocytes. Graphs display percent BrdU+ cells within the pre-proB population (B220+CD43+CD19-) as labeled. An E2AER/ER mouse receiving no BrdU injection was used as a negative control (plot displays pre-proB cells). The proB population (B220+CD43+CD19+) from BrdU injected E2A+/+ #2 is shown as a positive control for BrdU incorporation.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Additional file 4
###end title 77
###begin p 78
###xml 0 46 0 46 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequencing analysis of IgH V-DJ rearrangements</bold>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 177 181 177 181 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/+ </sup>
###xml 212 218 212 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink">ER/ER </sup>
###xml 341 342 341 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 348 349 348 349 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 350 351 350 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 642 643 642 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
###xml 650 651 650 651 <sub xmlns:xlink="http://www.w3.org/1999/xlink">H</sub>
Sequencing analysis of IgH V-DJ rearrangements. PCR products from the IgH V to DJ rearrangement analysis in Figure 6 were sequenced for the following Day 8 cultured samples: E2A+/+ (WT) tamoxifen treated, and E2AER/ER (ER) DMSO treated and tamoxifen treated. The total numbers of colonies sequenced per sample are shown. Sequences encoding VH1 to DHJH4 rearrangement products were determined. Unique rearrangement products were defined as products using a unique set of V, D, and J gene segments or containing a unique number of nucleotide additions/deletions. The average length of unique rearrangement products from the internal (Round 2) VH1 and JH4 primers is also shown for each sample analyzed.
###end p 78
###begin p 79
Click here for file
###end p 79
###begin title 80
Additional file 5
###end title 80
###begin p 81
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Phenotype of cultures utilized for IgH V-DJ rearrangement</bold>
###xml 142 143 142 143 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 147 149 147 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Phenotype of cultures utilized for IgH V-DJ rearrangement. Staining of Day 8 cultures for CD19 and IgM expression. Cells are pre-gated on 7AAD-B220+ lymphocytes. Relative percentages are displayed.
###end p 81
###begin p 82
Click here for file
###end p 82
###begin title 83
Acknowledgements
###end title 83
###begin p 84
###xml 93 97 <span type="species:ncbi:10090">mice</span>
We thank the Duke University transgenic facility for assistance with generating the knock-in mice, the Duke Comprehensive Cancer Center Flow Cytometry facility for help with cell sorting, Weiguo Zhang's lab for assistance with Western Blot analysis, and Adam Lazorchak for helpful discussions and technical support for EMSA analysis. This work was supported by funding from the National Institutes of Health to YZ.
###end p 84
###begin article-title 85
Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms
###end article-title 85
###begin article-title 86
Helix-loop-helix proteins and lymphocyte development
###end article-title 86
###begin article-title 87
New insights into E-protein function in lymphocyte development
###end article-title 87
###begin article-title 88
B-lymphocyte development is regulated by the combined dosage of three basic helix-loop-helix genes, E2A, E2-2, and HEB
###end article-title 88
###begin article-title 89
A heterodimer of HEB and an E12-related protein interacts with the CD4 enhancer and regulates its activity in T-cell lines
###end article-title 89
###begin article-title 90
Functions of E2A-HEB heterodimers in T-cell development revealed by a dominant negative mutation of HEB
###end article-title 90
###begin article-title 91
Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development
###end article-title 91
###begin article-title 92
###xml 15 20 <span type="species:ncbi:9606">human</span>
Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B
###end article-title 92
###begin article-title 93
Interactions between heterologous helix-loop-helix proteins generate complexes that bind specifically to a common DNA sequence
###end article-title 93
###begin article-title 94
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo
###end article-title 94
###begin article-title 95
Tissue-specific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor
###end article-title 95
###begin article-title 96
###xml 48 52 <span type="species:ncbi:10090">mice</span>
Ligand-activated site-specific recombination in mice
###end article-title 96
###begin article-title 97
###xml 58 62 <span type="species:ncbi:10090">mice</span>
Temporally and spatially regulated somatic mutagenesis in mice
###end article-title 97
###begin article-title 98
###xml 52 57 <span type="species:ncbi:10090">mouse</span>
A highly efficient ligand-regulated Cre recombinase mouse line shows that LoxP recombination is position dependent
###end article-title 98
###begin article-title 99
###xml 149 154 <span type="species:ncbi:10090">mouse</span>
Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse
###end article-title 99
###begin article-title 100
Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression
###end article-title 100
###begin article-title 101
Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy
###end article-title 101
###begin article-title 102
The helix-loop-helix gene E2A is required for B cell formation
###end article-title 102
###begin article-title 103
E2A proteins are required for proper B cell development and initiation of immunoglobulin gene rearrangements
###end article-title 103
###begin article-title 104
Promotion of cell cycle progression by basic helix-loop-helix E2A
###end article-title 104
###begin article-title 105
Regulation of E2A gene expression in B-lymphocyte development
###end article-title 105
###begin article-title 106
###xml 30 35 <span type="species:ncbi:10090">mouse</span>
###xml 52 57 <span type="species:ncbi:9606">human</span>
Functional replacement of the mouse E2A gene with a human HEB cDNA
###end article-title 106
###begin article-title 107
B cell development pathways
###end article-title 107
###begin article-title 108
Both E12 and E47 allow commitment to the B cell lineage
###end article-title 108
###begin article-title 109
Early B cell factor promotes B lymphopoiesis with reduced interleukin 7 responsiveness in the absence of E2A
###end article-title 109
###begin article-title 110
Gradient of E2A activity in B-cell development
###end article-title 110
###begin article-title 111
E47 is required for V(D)J recombinase activity in common lymphoid progenitors
###end article-title 111
###begin article-title 112
B-lineage differentiation in normal and transformed cells and the microenvironment that supports it
###end article-title 112
###begin article-title 113
Pax5 determines the identity of B cells from the beginning to the end of B-lymphopoiesis
###end article-title 113
###begin article-title 114
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
Systematic design and testing of nested (RT-)PCR primers for specific amplification of mouse rearranged/expressed immunoglobulin variable region genes from small number of B cells
###end article-title 114
###begin article-title 115
E-proteins directly regulate expression of activation-induced deaminase in mature B cells
###end article-title 115
###begin article-title 116
Differential functions for the transcription factor E2A in positive and negative gene regulation in pre-B lymphocytes
###end article-title 116
###begin article-title 117
E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells
###end article-title 117
###begin article-title 118
Long-term cultured E2A-deficient hematopoietic progenitor cells are pluripotent
###end article-title 118
###begin article-title 119
Ectopic expression of E47 or E12 promotes the death of E2A-deficient lymphomas
###end article-title 119
###begin article-title 120
E2A proteins promote development of lymphoid-primed multipotent progenitors
###end article-title 120
###begin article-title 121
E2A proteins maintain the hematopoietic stem cell pool and promote the maturation of myelolymphoid and myeloerythroid progenitors
###end article-title 121
###begin article-title 122
Important roles for E protein binding sites within the immunoglobulin kappa chain intronic enhancer in activating Vkappa Jkappa rearrangement
###end article-title 122
###begin article-title 123
Receptor editing and marginal zone B cell development are regulated by the helix-loop-helix protein, E2A
###end article-title 123
###begin article-title 124
Regulation of the helix-loop-helix proteins, E2A and Id3, by the Ras-ERK MAPK cascade
###end article-title 124
###begin article-title 125
E2A promotes the survival of precursor and mature B lymphocytes
###end article-title 125
###begin article-title 126
Thymocyte maturation is regulated by the activity of the helix-loop-helix protein, E47
###end article-title 126
###begin article-title 127
E2A and HEB Are Required to Block Thymocyte Proliferation Prior to Pre-TCR Expression
###end article-title 127
###begin article-title 128
Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen
###end article-title 128
###begin article-title 129
Virus-transformed pre-B cells show ordered activation but not inactivation of immunoglobulin gene rearrangement and transcription
###end article-title 129
###begin article-title 130
Immunoglobulin heavy and light chain genes rearrange independently at early stages of B cell development
###end article-title 130
###begin article-title 131
SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations
###end article-title 131

